Clinical Trials
11
Active:7
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 3:4
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (57.1%)Phase 1
3 (42.9%)A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
Phase 3
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 8179
- Registration Number
- NCT01492361
- Locations
- 🇺🇦
Amarin Investigational Site, Zaporizhzhia, Ukraine
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: PlaceboDrug: AMR101 (ethyl icosapentate) - 2 g/dayDrug: AMR101 (ethyl icosapentate) - 4 g/day
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 702
- Registration Number
- NCT01047501
- Locations
- 🇺🇸
Amarin Investigational Site, Wauwatosa, Wisconsin, United States
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: AMR101 (ethyl icosapentate) - 2 g/dayDrug: AMR101 (ethyl icosapentate) - 4 g/dayDrug: Placebo
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Amarin Pharma Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT01047683
- Locations
- 🇺🇦
Amarin Investigational Site, Odessa, Ukraine
News
HLS Therapeutics Secures Nova Scotia Reimbursement for Vascepa, Expanding Cardiovascular Drug Access to 95% of Eligible Canadians
HLS Therapeutics has secured a Product Listing Agreement with Nova Scotia Pharmacare for Vascepa (icosapent ethyl) reimbursement, effective July 1, 2025.
Recordati Secures Exclusive European Rights to Cardiovascular Drug Vazkepa in $175 Million Deal with Amarin
Recordati has acquired exclusive licensing and supply rights to commercialize Vazkepa (icosapent ethyl) across 59 European countries in a deal worth up to $175 million with Amarin.